Prostatype Genomics AB (OSTO:PROGEN) Asset Impairment Charge : kr0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Asset Impairment Charge?

Prostatype Genomics AB's Asset Impairment Charge for the three months ended in Jun. 2023 was kr0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was kr0.00 Mil.

Prostatype Genomics AB Asset Impairment Charge Historical Data

The historical data trend for Prostatype Genomics AB's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Asset Impairment Charge Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Asset Impairment Charge

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial											-	-	-	-	-

Prostatype Genomics AB Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Prostatype Genomics AB Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines